Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12316332 | 0.89 | HTT (0.53) | LRRK2DRD4POLBHTTGAA | |
| SCHEMBL12316330 | 0.89 | TDP1 (0.43) | LRRK2HTR4DRD4POLBHTT | |
| SCHEMBL12316370 | 0.89 | CA1 (0.51) | LRRK2HTR4DRD4CA1CA2 | |
| SCHEMBL6153477 | 0.86 | ROCK2 (0.52) | LRRK2HTR4DRD4RIPK2ERN1 | |
| SCHEMBL6153878 | 0.86 | ROCK2 (0.52) | LRRK2HTR4DRD4RIPK2ERN1 | |
| SCHEMBL6154410 | 0.86 | LRRK2 (0.49) | LRRK2HTR4DRD4RIPK2ERN1 | |
| SCHEMBL6153479 | 0.86 | ROCK2 (0.52) | LRRK2HTR4DRD4RIPK2ERN1 | |
| SCHEMBL6154397 | 0.86 | LRRK2 (0.49) | LRRK2HTR4DRD4RIPK2ERN1 | |
| SCHEMBL6154542 | 0.85 | HTR4 (0.58) | LRRK2HTR4DRD4RIPK2ERN1 | |
| Hydrochloric Acid SCHEMBL6154062 | 0.84 | HTR4 (0.57) | LRRK2HTR4DRD4RIPK2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | LRRK2 2548/4885KCNH2 2394/4885HTR4 2206/4885 |
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | LRRK2 3177/4885KCNH2 118/4885HTR4 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.